Barclays lowered the firm's price target on Rapid7 to $6.50 from $8 and keeps an Underweight rating on the shares post the Q1 report. The company's Q2 net new annual recurring revenue guidance is lower than expectations, which warrants estimate cuts, the analyst tells investors in a research note.
